CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 50,093	$ 22,954
Short-term investments	260,500	147,355
Accounts receivable, net	28,435	32,917
Inventory	21,337	23,969
Income taxes receivable	0	6,395
Prepaid expenses	1,237	1,182
Other current assets	7,311	2,657
Total current assets	368,913	237,429
Deferred income taxes, net	0	214
Intangible assets, net	291,420	299,606
Goodwill	105,250	103,370
Long-term portion of financial royalty assets, net	65,710	62,291
Property and equipment, net	15,135	15,607
Operating lease right-of-use assets	6,028	6,062
Finance lease right-of-use assets	3,219	3,393
Equity method investment in Primrose Bio	10,469	12,595
Other investments	36,500	36,726
Other assets	11,225	9,923
Total assets	913,869	787,216
Current liabilities:
Accounts payable	1,893	2,427
Accrued liabilities	12,430	12,467
Income taxes payable	1,138	0
Deferred revenue	1,227	1,222
Current contingent liabilities	127	256
Current operating lease liabilities	1,000	403
Current finance lease liabilities	3	7
Total current liabilities	17,818	16,782
Long-term deferred revenue	3,065	1,444
Long-term contingent liabilities	2,888	2,942
Deferred income taxes, net	50,606	31,622
Long-term operating lease liabilities	5,191	5,755
Other long-term liabilities	27,780	27,758
Total liabilities	107,348	86,303
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 60,000 shares authorized; 17,924 and 17,556 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	18	18
Additional paid-in capital	218,258	198,696
Accumulated other comprehensive loss	(910)	(817)
Retained earnings	589,155	503,016
Total stockholders' equity	806,521	700,913
Total liabilities and stockholders' equity	$ 913,869	$ 787,216